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Summary
Payout characteristics of Revalor-H and
Finaplix-H were measured in 30 heifers (678
pounds) assigned to one of six treatments: 1)
negative control, 2) melengestrol acetate
(MGA) (.5 mg/hd/d), 3) Finaplix-Hfi, 4)
Finaplix-H + MGA, 5) Revalor-Hfi, and 6)
Revalor-H + MGA.  Blood samples were
collected by jugular puncture on days 0, 1, 3, 5,
7, 13, 21, 28, 42, 56, 84, 112, and 140.
Following implantation with eith er Revalor-H or
Finaplix-H, serum trenbolone (TB) increased
markedly at 1 and 3 days after implantation,
then decreased through day 42.  A second peak
in serum TB was observ ed on day 56.  Between
days 56 and 84, a drop in serum TB was ob-
served.  Although TB in heifers implanted with
Revalor-H or Finaplix-H was lowes t between 84
and 140 days, the observed TB may still have
been adequate to modify heifer performance
over this period of time.  Aver age daily gain and
feed efficiency demonstrated an implant 
MGA interaction.  Heifers with no implant
responded to MGA supplementation with
increased rate of gain, whereas heifers receiving
either Revalor-H or Finaplix-H had less weight
gain when fed MGA.
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Introduction
Revalor-H is an implant recently approved
for use in feedlot heifers.  In order to help the
industry use it to its greatest potential,
information is needed relative to length
of payout and the relationship of circulating
levels of anabolic hormones to finishing heifer
performance.  In our study, concentrations of
trenbolone (TB) and estradiol (E2) in serum of
heifers implanted with Revalor-H and Finaplix-
H and fed with or without melengestrol acetate
(MGA) were measured.  Our objectives were to
determine the payout characteristics of the
implants and, to the extent that was possible, to
establish relationships between serum hormone
levels and performance
Experimental Procedures
Thirty heifer calves (678 pounds) with no
previous anabolic treatments were used.
Heifers were assigned to one of six treatments
(five heifers per treatment) :  1) negative control,
2) MGA (.5 mg/hd/d), 3) Finaplix-H, 4)
Finaplix-H + MGA, 5) Revalor-H, and 6)
Revalor-H + MGA.  Heifers were housed
individually and fed in open-front barns in a
140-day study.  Blood samples were collected
by jugular puncture twice (45 minutes apart) on
days 0, 1, 3, 5, 7, 13, 21, 28, 42, 56, 84, 112,
and 140.  All implants were made in the right
ears of heifers, and all blood samples were
collected from the right jugula r vein. Serum was
harvested, composited within day for each
animal, and analyzed for serum E2 and TB
concentrations.   Individual intakes were
measured, and feed refusals were collected and
weighed weekly.  At the conclusion of the
study, heifers were slaughtered in a commercial
packing plant, and carcass data were collected.
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Results and Discussion
Serum E2 concentration was not  affected by
feeding of MGA (data not shown).  However,
implantation with Revalor-H led to marked
increases in serum E2 (Figure 1).  Implantation
with Revalor-H increased serum E2 from an
initial level of 4 pg/ml to an average of 25 pg/ml
from day 1 to 13 after implantation.  Serum E2
then increased between days 21 and 56 after
implantation (average E2 over this period was
67 pg/ml) before dropping to an average value
of 19 pg/ml for days 84 through 140 after
implantation.   Although serum E2 remained
moderately elevated by Revalor-H implantation
for up to 140 days, a large drop was observed
between 56 and 84 days.
Serum TB concentrations remained essen-
tially zero for nonimplanted heifers, but
increased markedly  following implantation with
either Revalor-H or Finaplix-H.  Over the entire
experiment, serum TB was greater for heifers
receiving Finaplix-H than those receiving
Revalor-H (259 vs 204 p g/ml; Figure 2) and for
heifers fed MGA than those not fed MGA (187
vs 122 pg/ml; data not shown).  The overall
pattern of serum TB in r esponse to implantation
was similar for Finaplix-H and Revalor-H.  It
increased markedly at 1 and 3 days after im-
plantation, then decreased through day 42.  A
second peak in serum TB was observed on day
56.  Between days 56 and 84, a large drop in
serum TB was observed.  Although TB in
heifers implanted with Revalor-H or Finaplix-H
was lowest between 84 and 140 days, the
observed TB may still have been adequate to
modify heifer performance over this period of
time. 
Averaged over the entire experiment,
treatments did not alter feed intake (Table 1).
Average daily gain demonstrated an implant 
MGA interaction (P<.05).  Heifers with no
implant responded to MGA supplementation
with increased rate of gain, whereas heifers
receiving either Revalor-H or Finaplix-H had
less weight gain when fed MGA.  The de-
pression in ADG with MGA w as less for heifers
implanted with Finaplix-H than for those
implanted with Revalor-H.  Feed efficiency
showed a response simila r to ADG; heifers with
no implant were more efficient when fed MGA,
whereas heifers implanted with Revalor-H were
less efficient when fed  MGA.  Because dressing
percents were not affected by treatment, hot
carcass weights followed the same trends as did
gain (Table 2).  MGA supplementation
increased marbling score (P<.05).
Nonimplanted heifers tended to have larger
REA when fed MGA, whereas Revalor-H
implanted heifers tended to have smaller REA
when fed MGA.  In summary, anabolic agents
(implants or MGA) improved heifer
performance.  However, the effects of the
implants in combination with MGA were not
additive.
Table 1. Effect of Anabolic Treatment on Heifer Performance (140 days)
Implant
None Revalor-H Finaplix-H
Item 0 MGA 0 MGA 0 MGA SEM
No. heifers 5 5 5 5 5 5
Daily feed, lb DM 19.0 18.5 20.
1
19.1 19.
1
18.4 .8
Daily gain, lba 2.93 3.36 3.7
9
3.21 3.4
3
3.21 .19
Gain/Feeda .15 .18 .19 .17 .18 .17 .01
Implant  MGA interaction (P<.05).a
Table 2. Carcass Characteristics of Heifers with or without Anabolic Treatment
Implant
None Revalor-H Finaplix-H
Item 0 MGA 0 MGA 0  MGA SEM
Carcass wt, lba 680 700 759 676 709  686 17
Dressing % 61.8 61.7 61.9 60.7 60.8  61.2 .55
Back fat, in .79 .87 .78 .75 .66  .84 .12
KPH, % 2.6 2.8 3.0 2.7 2.9  2.9 .25
Marblingb 5.8 6.8 5.7 6.6 5.0  5.9 .44
REA, in2 10.5 11.6 12.2 11.1 11.7  11.4 .47
aImplant  MGA interaction (P<.05).
bEffect of MGA (P<.05).
Figure 1. Serum Estradiol Concentrations
Figure 2. Serum Trenbolone Concentrations
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